Aquilonius S M, Granat M, Hartvig P
Acta Neurol Scand. 1981 Jul;64(1):47-53. doi: 10.1111/j.1600-0404.1981.tb04384.x.
Defined daily doses per day and 10(3) inhabitants [Formula: see text] of the different types of antiparkinson agents have been compared in the period 1975-1979 for Norway, Sweden, Denmark and Finland. A marked increase in the utilization of L-DOPA containing drugs has taken place especially in Sweden following the introduction of the "combined drugs" (L-DOPA + decarboxylase inhibitor). Statistically, nearly all patients with parkinsonism in Sweden have since 1977 been treated with L-DOPA, while in the other nordic countries about 10% of the patients are not on this therapy. These data are discussed in relation to the current concept of pharmacotherapy of parkinsonism. Further, many patients treated with neuroleptic drugs do in addition take anticholinergic agents. Drug utilization figures indicate this method of treatment to be most common in Denmark and Sweden.
1975年至1979年期间，对挪威、瑞典、丹麦和芬兰不同类型抗帕金森药物的每日规定剂量和每10³居民的用量[公式：见正文]进行了比较。自“复方药物”（左旋多巴+脱羧酶抑制剂）引入后，含左旋多巴药物的使用量显著增加，尤其是在瑞典。从统计学角度来看，自1977年以来，瑞典几乎所有帕金森病患者都接受了左旋多巴治疗，而在其他北欧国家，约10%的患者未接受这种治疗。结合帕金森病药物治疗的当前概念对这些数据进行了讨论。此外，许多接受抗精神病药物治疗的患者还同时服用抗胆碱能药物。药物使用数据表明，这种治疗方法在丹麦和瑞典最为常见。
